TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04470115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks
Description: The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
Study: NCT01844674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast \>/= 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
Study: NCT05621694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Easy
Description: A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
Study: NCT02053857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-P

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study: NCT01952522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weighted brace
Description: People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
Study: NCT02415985

Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/r will be supplied by NHSO/GPO
Description: 200/50 mg tablet LPV/rtv

Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/r will be supplied by NHSO/GPO
Description: 200/50 mg tablet LPV/rtv

Intervention type: DRUG
Group type: OTHER
Intervention: Rifabutin

Intervention type: DRUG
Group type: OTHER
Intervention: Rifabutin
Study: NCT01200914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Description: The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA alone without use of the GORE VIABAHN
Description: Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
Study: NCT01616927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide will be administered once every 4 weeks as a subcutaneous injection
Study: NCT02165527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lunar iXDA scan
Description: Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
Study: NCT01865773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFR dialysis
Description: HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
Study: NCT02803463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open appendectomy with peritoneal closure
Description: open appendectomy with peritoneal closure under general anesthesia for acute appendicitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open appendectomy without peritoneal closure
Description: open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
Study: NCT04174261

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Preprocedural ticagrelor loading and standard dose thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Preprocedural ticagrelor loading and standard dose thereafter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Preprocedural remote ischemic preconditioning on the non-dominant arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Preprocedural remote ischemic preconditioning on the non-dominant arm

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Preprocedural clopidogrel loading and standard dose thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Preprocedural clopidogrel loading and standard dose thereafter
Study: NCT02196831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesamorelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance that looks like tesamorelin
Study: NCT02747160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Anxiety from Cancer (MAC)
Description: The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
Study: NCT01855373

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEAK ATP® with GlycoCarn®
Description: PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEAK ATP®
Description: PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlycoCarn®
Description: GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo: 2 capsules twice daily on an empty stomach
Study: NCT00134420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutropin AQ
Description: Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arginine and Clonidine Stimulation Testing
Description: This testing was done to determine growth hormone status prior to starting treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arginine and Clonidine Stimulation Testing
Description: This testing was done to determine growth hormone status prior to starting treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Growth Factors Laboratory Testing
Description: This involved assessment of growth factors such as IGF#1 before treatment was initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Growth Factors Laboratory Testing
Description: This involved assessment of growth factors such as IGF#1 before treatment was initiated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neuropsychological Testing
Description: This testing was done prior to treatment and at the end of treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Testing
Description: This testing was done prior to treatment and at the end of treatment.
Study: NCT04134403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STASIS
Description: Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
Study: NCT00573287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: clozapine--tabs, 450mg. max, daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone--tabs, 6mg max, daily, 24 weeks
Study: NCT01890720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNPWT
Description: The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative wound dressing
Description: A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
Study: NCT03320694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
Study: NCT00736047

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NIC002

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01773447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Set-back suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical mattress suture
Study: NCT04089800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone based multimedia application
Description: The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
Study: NCT01044329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal, 1.25 mg, 3 times, one month apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal, 2 mg, 2 times, two months apart.
Study: NCT02492737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Study: NCT02444000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy alone
Description: PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy+PCV chemotherapy
Description: Radiotherapy followed by 6 cycles of PCV
Study: NCT03269162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinfukang Koufuye
Description: 30ml per time, tid, po (d6-21, q21)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2,ivgtt 30mins, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2,ivgtt 30mins, d1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m2, ivgtt 30mins, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2, ivgtt 30mins, d1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2, ivgtt \>2h, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2, ivgtt \>2h, d1
Study: NCT00882570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
Study: NCT05349253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic extracts
Description: One intake in total

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intake in total
Study: NCT00728143

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Highly viscous polysaccharide enriched biscuits
Description: 10 g of highly viscous polysaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highly viscous polysaccharide enriched biscuits
Description: 10 g of highly viscous polysaccharide
Study: NCT01341392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study: NCT01932606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrite
Description: Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo for Nitrite
Description: Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
Study: NCT02783625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvelisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvelisib
Study: NCT04480879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 nebuliser
Description: Nebuliser suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 Monodose DPI presented in capsules
Description: AZD8154 Monodose DPI formulation delivered dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD8154 Placebo Monodose DPI presented in capsules
Description: The dose correspond to AZD8154 Monodose DPI formulation
Study: NCT01341392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodiopine
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 amlodipine
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Study: NCT02346890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Study: NCT01488344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple kinase inhibitor BIBF1120
Description: triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
Study: NCT00061282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clotrimazole
Description: One retention enema, administered nightly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: One retention enema, administered nightly
Study: NCT03139513

Intervention type: DRUG
Intervention: Cobimetinib
Description: Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
Study: NCT02781974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
Study: NCT03755622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transpalatal Arch (TPA)
Description: In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
Study: NCT00061282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: One retention enema, administered nightly
Study: NCT04504058

Intervention type: OTHER
Intervention: routine clinical treatment
Description: Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
Study: NCT01962168

Intervention type: DEVICE
Intervention: Evolution® Biliary Stent - Uncovered
Description: Commercially available device
Study: NCT00701623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: patients will receive the application of one of two types of heparin directly on the injured area
Study: NCT03755622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpalatal Arch (TPA) fabricated from 3D reconstructed model
Description: In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
Study: NCT03677674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Participants will be dehydrated (2% of their body weight) using sauna.
Study: NCT01973283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medication
Description: If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
Study: NCT03139513

Intervention type: DRUG
Intervention: Vemurafenib
Description: Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
Study: NCT01101100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: 210 mg SC or 140 mg SC
Study: NCT03881371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
Study: NCT00701623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folder water
Description: patients will receive the application of folder water directly on the injured area
Study: NCT02068768

Intervention type: DEVICE
Intervention: Avenue® L Interbody Fusion System (LDR Spine)
Description: PEEK, intervertebral cage for interbody fusion of the lumbar spine
Study: NCT01216371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Study: NCT00344942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 220µg/day or a double spray into each nostril once daily for 12 weeks'treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a double spray into each nostril once daily
Study: NCT03460015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped.
Study: NCT02674854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%/0.005%
Description: 1 drop daily in the evening (PM) in both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) ophthalmic solution 0.02%
Description: 1 drop daily in the evening (PM) in both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Description: 1 drop daily in the evening (PM) in both eyes (OU)